AI assistant
Pacira BioSciences, Inc. — Director's Dealing 2011
Feb 2, 2011
32125_dirs_2011-02-02_719bb698-f2a1-4368-9202-3b4bd4fd24ba.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Pacira Pharmaceuticals, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2011-02-02
Reporting Person: Walters Mark (SVP, Technicnical Operations)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.61 | 2020-09-02 | Common Stock (37192) | Direct | |
| Stock Option (Right to Buy) | $1.61 | 2020-09-02 | Common Stock (13947) | Direct | |
| Stock Option (Right to Buy) | $5.49 | 2020-12-29 | Common Stock (18348) | Direct |
Footnotes
F1: The option vests as to 75% of the option shares on September 2, 2010 and, as to the remaining 25% of the option shares, in successive equal monthly installments for the subsequent 12 months. The option shares become exercisable, to the extent vested, from and after the Issuer's initial public offering.
F2: The option vests as to 25% of the option shares on September 2, 2011 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months. The option shares become exercisable, to the extent vested, from and after the Issuer's initial public offering.
F3: The option vests as to 25% of the option shares on December 29, 2011 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months. The option shares become exercisable, to the extent vested, from and after the Issuer's initial public offering.